Spark Therapeutics Profile

55.02
USD 0.83  1.53%
78%
93%

Spark Therapeutics exotic insider transaction detected

Spark Therapeutics Inc insider trading alert for general transaction of restricted stock units by Lisa Dalton, Head of Human Resources, on February 23, 2018. This event was filed by Spark Therapeutics Inc with SEC on 2018-02-23. Initial filing of beneficial ownership - SEC Form 3 [view details]   

Spark Therapeutics Summary

Spark Therapeutics Inc (ONCE) is traded on NASDAQ in USA. It is located in PENNSYLVANIA, U.S.A and employs 213 people. Spark Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 1.9 B. Spark Therapeutics Inc conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 37.01 M outstanding shares of which 2.89 M shares are now shorted by private and institutional investors with about 5.68 trading days to cover. N/A currently holds about 478.7 M in cash with (156.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.94.
Check Spark Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares5.6 M285.4 M
Price T Rowe Associates IncCommon Shares4.1 M212.2 M
Ecor1 Capital LlcCall Options455.5 K23.4 M
View Spark Therapeutics Diagnostics

Selected Spark Therapeutics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Spark Therapeutics Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
< 29% 
Equity ratings for Spark Therapeutics Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 213 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameSpark Therapeutics Inc
CEO, Co-Founder, DirectorJeffrey MarrazzoAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationPENNSYLVANIA, U.S.A
Business Address3737 Market Street
ExchangeNASDAQ
CIK Number01609351.0
CUSIP84652J103
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.sparktx.com
Contact Number215 220 9300
CurrencyUSD - US Dollar

Recommendations

Spark Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
66.83Buy12Odds
Spark Therapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Spark Therapeutics Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Spark Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-1.35May 3, 2017
Spark Therapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Spark Therapeutics Corporate Directors
Robert Perez Director
Lars Ekman Independent Director, Ph.D
Lorris Betz Director